Ever Supreme Bio Technology Co., Ltd (6712.TWO)

213.00 -1.00 (-0.47%) As of 01:03PM CST. Market open.

Ever Supreme Bio Technology Co., Ltd

Rm. A, No. 573, Taiwan Blvd.
10F., Sec. 2 West Dist.
Taichung 403
Taiwan
886 4 2325 2888
https://www.ever-supreme.com.tw

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Description

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to immune cells and stem cells. Its products include UMC01, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke; ADCV01, a drug candidate in Phase II clinical trials for the treatment of malignant brain tumor; CAR001, a chimeric antigen receptor immune cells product; and bone-marrow stem cells (BMSC), used to treat chronic stroke, degenerative osteoarthritis, and spinal cord injuries. The company was founded in 2016 and is based in Taichung, Taiwan.

Corporate governance

Ever Supreme Bio Technology Co., Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.